Roche Australia's Statement on COVID-19 (novel coronavirus)
SYDNEY, 12 March 2020 – The World Health Organization (WHO) declared COVID-19 (novel coronavirus) a Pandemic on 11 March 2020. Locally, the Australian Government activated the Australian Health Sector Emergency Response Plan for Novel Coronavirus (COVID-19), on 27 February 2020, based on the latest and best medical advice. This action by the Australian Government reflects concerns around COVID-19 as a serious health issue.
Roche Australia’s thoughts are with all Australians who have been impacted by COVID-19 and their families, friends and loved ones. We also extend our sincere appreciation to all Australian healthcare professionals and allied health workers who are at the frontline of the COVID-19 response.
Roche’s commitment to the response for COVID-19
Roche recognises that a collaborative approach between public and private sectors across the globe, and within Australia, is required to effectively manage this developing situation. As a healthcare company, we are dedicated to working with local and global health authorities to provide any support we can to assist with any response to COVID-19.
There are currently no medicines proven to be effective in the treatment of COVID-19. However, as infectious diseases form a core area of our pharmaceutical research and clinical development focus, we are supporting the WHO and other relevant stakeholders as necessary, to provide expertise and advice on these cases of human coronavirus.
Ensuring supply of medicines for Australian patients
With regards to the supply of our medicines and therapies, we have initiated plans to ensure the outbreak of COVID-19 does not impact supply in Australia and feel confident in our ability to continue to provide medicines to patients for the foreseeable future. We continue to monitor demand to mediate potential supply risks. Based on current demand forecasts, we do not anticipate supply interruptions or shortages for any Roche product currently available for Australian patients.
We encourage all members of the community to follow the advice from the Health Minister, Chief Medical Officer and relevant health authorities, such as the Therapeutic Goods Administration (TGA), regarding accessing their prescription medicines as per normal practice. There is currently no need to stockpile supply of prescription medicines in anticipation of further spread of COVID-19.
Supply of Medicines
Roche maintains a Business Continuity Program that includes dedicated provision for responding to a pandemic situation. This includes local, regional and global demand planning systems to provide early warnings of potential shortages of medicines. This response has now been activated. We are working closely with our customers to monitor demand locally to ensure that, should the COVID-19 outbreak become more widespread, we can maintain supply as required.
Roche does not manufacture any of our medicines in Australia, and none of the medicines we supply to Australian patients are manufactured in China.
Globally, we are assessing our supply chains and our suppliers’ supply chains for components and raw materials sourced from impacted countries, including China, as we determine the coverage and potential impact due to the COVID-19 outbreak. As of now, we have not identified any critical component that would affect our ability to supply medicines in the near future, based on current demand forecast.
All Roche global manufacturing sites adhere to specific pandemic plans and guidance, including preventative measures to reduce infection risks and social distancing measures to minimise social contacts. These sites also abide by comprehensive global hygiene and gowning standards and processes to safeguard against potential contamination or cross-contamination.
Supply of Diagnostic Tests
As a leader in diagnostics, Roche is committed to providing testing solutions for the world’s most challenging healthcare emergencies. We are delivering as many tests as possible, within the limits of supply.
Roche Diabetes Care Products
We are closely monitoring the situation. Our product supply is assured. The delivery of products to/from affected countries is stable. Roche Diabetes Care's production is up and running. Our warehouse stock is sufficiently covered to avoid customer backorders on a global and local level. All Accu-Chek products are available as usual.
For daily updates on COVID-19 in Australia and access to important information and resources, please visit the Australian Government Department of Health site, at: https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert
For all media enquiries, please contact Roche Products Pty Limited:
Jenny Walters +61 407 929243
Rachael Bylykbashi +61 427 384 344
For all media enquiries specific to Roche Diagnostics Limited, please contact:
Allison Rossiter +61 436 455 257
For all media enquiries specific to Roche Diabetes Care Pty Limited, please contact:
Anne-Maree Toohey +61 450 342 820